Determining MDR1/P-glycoprotein expression in breast cancer

International Journal of Cancer

Volumn 93, Issue 1, 2001, Pages 114-122

  Faneyte, Ian F ^a   Kristel, Petra M P ^a   Van De Vijver, Marc J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Breast cancer; MDR1; Multidrug resistance; P glycoprotein; Real time RT PCR

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL MEMBRANE; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0035399830     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010701)93:1<114::AID-IJC1309>3.0.CO;2-J     Document Type: Article

References (48)

1. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
2. Locally advanced breast cancer
3. Combined sequential approach in locally advanced breast cancer
4. Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers
5. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
6. Sequential chemotherapy, surgery and radiotherapy in locally advanced breast cancer
7. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer
8. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
9. Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug-resistant human cells
10. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells
11. Genetic dissection of the function of mammalian P-glycoproteins
12. The physiological function of drug-transporting P-glycoproteins
13. Normal viability and altered pharmacokinetics in mice lacking MDR1-type (drug-transporting) P-glycoproteins
14. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule
15. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells
16. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein
17. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line
18. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines
19. Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
20. Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland
21. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene
22. Monoclonal antibody JSB1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance
23. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug resistant human ovarian carcinoma cell lines
24. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
25. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
26. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers
27. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy
28. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer
29. MDR1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy
30. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
31. MDR1 gene expression in primary and advanced breast cancer
32. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma
33. Over-expression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol
34. Wosikowski K, Schuurhuis D, Kops GJ, Saceda M, Bates SE, Altered gene expression in drug-resistant human breast cancer cells
35. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer
36. Randomized phase II study of single-agent epirubicin ± verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial
37. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial
38. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen
39. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
40. P-glycoprotein: Clinical significance and methods of analysis
41. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers
42. A multidrug resistance transporter from human MCF-7 breast cancer cells
43. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
44. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: Relationships to drug exposure, p53 mutations and clinical outcome of the patients
45. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes
46. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype
47. P-glycoprotein expression and function in circulating blood cells from normal volunteers
48. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T-lymphocytes